



Bioanalytical Solutions for Immuno-oncology Therapeutics

Cancer remains one of the most complex and difficult to treat diseases and is a leading cause of death worldwide. Advances in the understanding of the immune systems holds great promise for treatment solutions.

Synexa Life Sciences is a specialist in complex biomarker and bioanalytical assay development, execution and interpretation, providing bespoke assay solutions in an integrated, sciencedriven and quality-orientated approach.

Our expertise in the field of immunology and immune-based analytical technologies makes us the perfect partner in advancing immuno-oncology therapeutic pipelines.

Several approaches are currently being investigated in the immuno-oncology space, focusing on using the already existing immune mechanisms to treat the tumour, with particular emphasis being placed on:

- Monoclonal antibodies
- Checkpoint inhibitors
- CAR-T cell therapies
- Immunomodulatory therapies

We have validated assays for the assessments of each of these and novel modalities as well as the required expertise for custom development and validation of bespoke assays, from a wide array of matrices spanning the biological continuum.

SOLUTIONS THAT SERVE AT THE FOREFRONT OF THERAPEUTIC DEVELOPMENT

IO Services

We use innovative approaches and validated platforms to answer client-specific questions for quality, clinically-relevant data.

Our validated and physiologically-relevant assay formats are developed to the highest standard and according to regulatory guidelines to assess:

🖉 Target Engagement

Ľ

Assessment of target engagement quantifies the effects of the therapy on the immune system, providing integral early insight into the therapeutic's activity, saving time and money on molecules with less than optimal engagement.

🖔 Expression of Pharmacology

Data obtained to quantify the effects of the immune system on the malignancy is best studied in an integrated manner by utilizing biomarkers from across the biological continuum, from DNA through to Tissue.

Flow Cytometry Services

A crucial tool in our arsenal of investigative technologies, flow cytometry is a mainstay of our immuno-oncology therapy assessments.

Synexa Life Sciences is positioned at the forefront of the rapidly expanding field of flow cytometry, led by leaders in the field with decades of experience and supported by robust and proven technology platforms, harmonised across our strategically located labs to support our global client base with quality, scientifically sound clinical data.

We are fully capable of managing samples through the complete analytical cycle, with dedicated project, logistics and sample management policies.

Immuno-profiling & Phenotyping Assays

Target engagement/PK/PD Assays

- Lymphocytes (TN, $T_{_{H'}}, T_{_{FH'}}, T_{_{reg'}}, T_{_{EFF'}}, T_{_{EM'}}, T_{_{CM'}}$ NK and B cells)
- Dendritic cells (DCs)
- Monocytes
- Macrophages
- Myeloid-derived suppressor cells (MDSCs)
- Multimers
- Intracellular staining
- T_{req} polarization assessment

-

- Receptor Occupancy assays
- Phospho-flow assays
- Polyamine uptake assessment
- SARS-CoV-2 immune response
 assessment
- Flow cytometry-based PK assessment.

Functional Assays

- Cytokine expression
- Cytotoxic markers
- Activation markers
- Proliferation assays
- Basophil degranulationRare cell detection and
- quantificationAntibody-dependant cellular cytotoxicity (ADCC)
- Complement-dependant cytotoxicity (CDC)
- Small particle detection and analysis
- ELISpot assays

Case Study Applications

Platelet-derived circulation microparticles (cMP) Detection of cMPs expressing Annexin V, CD41, CD9 or CD63

Immunophenotyping: Rare event analysis

Detection of antigen specific vaccine responses using pentamers







Get in Touch

- ContactUs@synexagroup.com
- www.synexagroup.com
- Life Sciences, BV 2020. All rights reserved.